(Q37956829)

25 August 2017

1 reference

title

Inborn 'errors' of drug metabolism. Pharmacokinetic and clinical implications (English)

1 reference

25 August 2017

1 reference

Lennard MS

1

1 reference

25 August 2017

Tucker GT

series ordinal

2

1 reference

25 August 2017

Woods HF

series ordinal

3

1 reference

25 August 2017

1 October 1990

1 reference

Clinical Pharmacokinetics

25 August 2017

1 reference

25 August 2017

19

1 reference

25 August 2017

4

1 reference

25 August 2017

257-263

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-199019040-00001

25 August 2017

0 references

cites work

Mechanism of hypersensitivity reactions: proposed involvement of reactive metabolites generated by activated leukocytes

1 reference

12 December 2020

Succinylcholine and malignant hyperthermia

1 reference

12 December 2020

Poor sulphoxidation ability in patients with food sensitivity

1 reference

12 December 2020

Treatment of hypertension with beta-adrenoceptor blocking drugs

1 reference

12 December 2020

A proposed mechanism for chlorpromazine jaundice--defective hepatic sulphoxidation combined with rapid hydroxylation.

1 reference

12 December 2020

Genetic variation in the human hepatic cytochrome P-450 system

1 reference

12 December 2020

Human pharmacogenetics: Introduction

1 reference

12 December 2020

Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications

1 reference

12 December 2020

Inheritance of phenytoin hypometabolism: a kinetic study of one family

1 reference

12 December 2020

Polymorphic O-demethylation of codeine

1 reference

12 December 2020

The effects of diabetes mellitus, exercise, and single doses of biguanides upon lactate metabolism in man

1 reference

12 December 2020

The Relationship between Chemical Constitution and Taste

1 reference

12 December 2020

The nature of the defect in tyrosine metabolism in alcaptonuria

1 reference

12 December 2020

1 reference

12 December 2020

Metabolic oxidation phenotypes as markers for susceptibility to lung cancer

1 reference

12 December 2020

High incidence of poor sulfoxidation in patients with primary biliary cirrhosis

1 reference

12 December 2020

Impaired oxidation of debrisoquine in patients with perhexiline neuropathy

1 reference

12 December 2020

Genetic factors related to glaucoma

1 reference

12 December 2020

Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--histograms and probit plots

1 reference

12 December 2020

Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism

1 reference

12 December 2020

Drug metabolism in liver disease

1 reference

12 December 2020

HEREDITARY TRANSMISSION OF EXCEPTIONAL RESISTANCE TO COUMARIN ANTICOAGULANT DRUGS. THE FIRST REPORTED KINDRED.

1 reference

12 December 2020

1 reference

12 December 2020

Genetic factors influencing the metabolism of tolbutamide

1 reference

12 December 2020

Methyltransferase pharmacogenetics

1 reference

12 December 2020

Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis

1 reference

12 December 2020

[Enzymatic inactivation of isonicotinic acid hydrizide in human and animal organism]

1 reference

12 December 2020

Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations

1 reference

12 December 2020

Polymorphisms of antipyrine and theophylline metabolism in man: molecular and clinical implications

1 reference

12 December 2020

Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.

1 reference

12 December 2020

Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity

1 reference

12 December 2020

Sulfotransferase pharmacogenetics

1 reference

12 December 2020

Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors

1 reference

12 December 2020

In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans.

1 reference

12 December 2020

Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine

1 reference

12 December 2020

The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects

1 reference

12 December 2020

Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity

1 reference

12 December 2020

S-methylation in motorneuron disease and Parkinson's disease

1 reference

12 December 2020

Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?

1 reference

12 December 2020

Structural requirements for bioactivation of anticonvulsants to cytotoxic metabolites in vitro

1 reference

12 December 2020

In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme

1 reference

12 December 2020

Pharmacogenetics of aldehyde dehydrogenase (ALDH).

1 reference

12 December 2020

Debrisoquine oxidation phenotype and susceptibility to lung cancer

1 reference

12 December 2020

Pharmacogenetics of alcohol dehydrogenase (ADH).

1 reference

12 December 2020

What therapeutic drugs should be monitored?

1 reference

12 December 2020

Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal

1 reference

12 December 2020

Genetic predisposition to phenytoin-induced birth defects

1 reference

12 December 2020

The value of therapeutic drug monitoring to the practising physician--an hypothesis in need of testing

1 reference

12 December 2020

Impaired oxidation of debrisoquine in patients with perhexiline liver injury

1 reference

12 December 2020

UDP-glucuronosyltransferases

1 reference

12 December 2020

Genetic polymorphism of S-mephenytoin hydroxylation

1 reference

12 December 2020

Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs

1 reference

12 December 2020

Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine

1 reference

12 December 2020

Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus

1 reference

12 December 2020

Influence of oxidation polymorphism on phenformin kinetics and dynamics

1 reference

12 December 2020

A method for the detection of atypical forms of human serum cholinesterase; determination of dibucaine numbers

1 reference

12 December 2020

Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation

1 reference

12 December 2020

Genetic polymorphism of trimethylamine N-oxidation

1 reference

12 December 2020

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

1 reference

12 December 2020

Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--hypothesis testing

1 reference

12 December 2020

Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia

1 reference

12 December 2020

Xenobiotic metabolism in motor neuron disease

1 reference

12 December 2020

Genetic aspects of the polymodally distributed sulphoxidation of S-carboxymethyl-L-cysteine in man.

1 reference

12 December 2020

Oxidation polymorphism has clinical relevance

1 reference

12 December 2020

10.2165/00003088-199019040-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

0 references

1 reference